LAVA Therapeutics (LVTX)
(Delayed Data from NSDQ)
$1.63 USD
-0.05 (-2.98%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.67 +0.04 (2.45%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Cash flow Statements
Fiscal Year End for LAVA Therapeutics NV falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -41.70 | -31.66 | -45.19 | -15.48 | NA |
Depreciation/Amortization & Depletion | -0.62 | 0.65 | 1.00 | 0.46 | NA |
Net Change from Assets/Liabilities | -2.83 | 34.11 | 10.84 | 4.32 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 6.17 | 0.94 | 4.70 | 1.03 | NA |
Net Cash From Operating Activities | -38.97 | 4.04 | -28.65 | -9.67 | NA |
Property & Equipment | -0.73 | -0.59 | -0.76 | -0.50 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | -16.91 | 9.93 | -42.78 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -17.64 | 9.35 | -43.55 | -0.50 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.02 | 150.82 | 16.51 | NA |
Issuance (Repayment) of Debt | 0.47 | 0.61 | 0.68 | 2.06 | NA |
Increase (Decrease) Short-Term Debt | -1.04 | -0.34 | -0.34 | -0.24 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Financing Activities | -0.57 | 0.28 | 151.16 | 18.32 | NA |
Effect of Exchange Rate Changes | 1.08 | -4.21 | -3.92 | -0.92 | NA |
Net Change In Cash & Equivalents | -56.10 | 9.46 | 75.05 | 7.24 | NA |
Cash at Beginning of Period | 100.33 | 90.87 | 15.82 | 7.48 | NA |
Cash at End of Period | 44.23 | 100.33 | 90.87 | 14.71 | NA |
Diluted Net EPS | -1.57 | -1.23 | -2.30 | -8,592.02 | NA |
Fiscal Year End for LAVA Therapeutics NV falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -8.70 | -0.48 | -41.70 | -35.26 | -26.47 |
Depreciation/Amortization & Depletion | -0.87 | -0.43 | -0.62 | -0.29 | -0.28 |
Net Change from Assets/Liabilities | -0.71 | -0.58 | -2.83 | 3.23 | 1.63 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.77 | 0.37 | 6.17 | 3.47 | 3.73 |
Net Cash From Operating Activities | -9.51 | -1.13 | -38.97 | -28.85 | -21.40 |
Property & Equipment | 0.09 | 0.09 | -0.73 | -0.73 | -0.72 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.97 | 0.63 | -16.91 | -8.22 | 8.62 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 1.06 | 0.72 | -17.64 | -8.95 | 7.90 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 0.26 | 0.13 | 0.47 | 0.35 | 0.24 |
Increase (Decrease) Short-Term Debt | -0.28 | -0.14 | -1.04 | -0.74 | -0.49 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.01 | 0.00 | -0.57 | -0.39 | -0.25 |
Effect of Exchange Rate Changes | -0.70 | -0.64 | 1.08 | 0.52 | 1.03 |
Net Change In Cash & Equivalents | -9.15 | -1.04 | -56.10 | -37.67 | -12.73 |
Cash at Beginning of Period | 44.23 | 44.23 | 100.33 | 100.33 | 100.33 |
Cash at End of Period | 35.09 | 43.19 | 44.23 | 62.66 | 87.61 |
Diluted Net EPS | -0.31 | -0.02 | -0.22 | -0.34 | -0.48 |